Proximagen inks drug development deal
Proximagen Neuroscience has signed an agreement with Biovitrum to acquire Biovitrum's wholly owned subsidiary Cambridge Biotechnology, along with certain drug development programmes.

Proximagen Neuroscience has signed a sale and purchase agreement with Biovitrum to acquire Biovitrum's wholly owned subsidiary Cambridge Biotechnology (CBT), along with certain drug development programmes, directly from Biovitrum.
In consideration for these acquisitions, London-based Proximagen will pay Biovitrum a percentage of future revenues generated from the acquired drug development programmes. The transaction is expected to be completed by the end of November.
As part of the acquisition, Proximagen will acquire certain CBT programmes, as well as two clinical-stage programmes (the 5-HT2c agonist programme and the 5-HT6 cognition programme) and a number of pre-clinical-stage programmes including VAP-1 and TrkA from Biovitrum.
The acquisition of CBT is said to be consistent with the strategy stated by Proximagen at the time of its £50m fundraising in June 2009 of raising capital to acquire later-stage drug development programmes and to further develop these programmes to commercialisation.
CBT, which had unaudited net assets of £109,000 as of 30 September 2009, will be acquired on a cash-free/debt-free basis and has not generated any third-party revenues.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Construction industry lags in tech adoption
Are these the best people to ask "Insights from 2,000 Industry Leaders"? - what would their customers views be like (perhaps more...